Skip to main content
RVVTF logo

Revive Therapeutics Ltd. (RVVTF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.0071 -$0.0029 (-29.00%)
MCap: $3.16M| Vol: 113.0K|

Market cap $3.16M is the value of all shares combined.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

Revive Therapeutics Ltd. (RVVTF) trades at $0.0071. Revive Therapeutics Ltd. is a pharmaceutical company focused on developing therapeutics for rare disorders and infectious diseases. Market cap: $3.16M, Sector: Healthcare.

Price as of · Last analyzed: Mar 15, 2026
Revive Therapeutics Ltd. is a pharmaceutical company focused on developing therapeutics for rare disorders and infectious diseases. Their pipeline includes treatments for COVID-19, methamphetamine use disorder, and autoimmune hepatitis.

Analyst Coverage for RVVTF: RVVTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • YCBD · cbdMD, Inc. · 23 /100
  • AKAN · Akanda Corp. · 18 /100
  • QNTM · Quantum BioPharma Ltd. · 30 /100

See all scored stocks →

Revive Therapeutics Ltd. (RVVTF) Healthcare & Pipeline Overview

CEOMichael Frank
Employees3
HeadquartersToronto, CA
IPO Year2015

Revive Therapeutics Ltd. is a life sciences company focused on developing cannabinoid and psilocybin-based pharmaceuticals for rare inflammatory diseases and infectious diseases like COVID-19. Their lead drug candidate, Bucillamine, is in Phase 3 clinical trials, positioning the company within the specialty and generic drug manufacturing sector.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 15, 2026

What Is the Investment Thesis for RVVTF?

AI-written as of Mar 15, 2026 — figures and tone reflect the data available then, not today's score.

Revive Therapeutics presents a high-risk, high-reward investment profile typical of early-stage pharmaceutical companies. The primary value driver is the successful completion of Phase 3 clinical trials for Bucillamine, targeting infectious diseases. Positive trial results could lead to regulatory approval and subsequent revenue generation. The company's research into psilocybin-based therapies for mental health disorders and substance abuse represents a longer-term growth opportunity. However, the company's small market capitalization of $3.16M and negative P/E ratio of -2.44 indicate significant financial risks. Investors should carefully consider the inherent uncertainties associated with drug development and regulatory approval processes.

Based on FMP financials and quantitative analysis

RVVTF Key Highlights

AI-written as of Mar 15, 2026 — figures and tone reflect the data available then, not today's score.

Bucillamine is currently in Phase 3 clinical trials for the treatment of infectious diseases, including COVID-19.

  • The company has a cannabinoid pharmaceutical portfolio focused on rare inflammatory diseases.
  • Revive Therapeutics has research collaboration agreements with multiple universities and PharmaTher Inc. to expand its drug development pipeline.
  • The company is developing Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder.
  • The company's market capitalization is $3.16M.

Who Are RVVTF's Competitors?

RVVTF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
CPIVF Captiva Verde Wellness Corp. $0.10 0.00% $30.5M —
YCBD cbdMD, Inc. $0.38 +1.42% $5.10M —
AKAN Akanda Corp. $3.43 -14.89% $9.05M —
QNTM Quantum BioPharma Ltd. $1.42 -6.58% $9.13M 30 5-pillar
IMCC IM Cannabis Corp. $0.54 +8.49% —
BFRI Biofrontera Inc. $0.60 +1.10% $10.8M —
COSM COSM $2.95 +3.51% $14.8M —
SHPH Shuttle Pharmaceuticals Holdings, Inc. $3.90 +2.01% $18.6M 32 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RVVTF's Key Strengths?

Promising drug pipeline with Bucillamine in Phase 3 trials.

  • Focus on unmet medical needs in rare disorders and infectious diseases.
  • Strategic research collaborations with universities and PharmaTher Inc.
  • Development of both cannabinoid and psilocybin-based therapeutics.

What Are RVVTF's Weaknesses?

Limited financial resources and small market capitalization.

  • Dependence on successful clinical trial outcomes and regulatory approvals.
  • Early-stage development of psilocybin-based therapies.
  • Small number of employees.

What Are the Key Risks for RVVTF?

Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.

  • Failure to obtain regulatory approval for Bucillamine or other drug candidates.
  • Unfavorable clinical trial results.
  • Competition from larger pharmaceutical companies with greater resources.
  • Dependence on securing additional funding to support research and development.
  • Changes in government regulations regarding cannabinoid and psilocybin-based therapies.

What Are RVVTF's Competitive Advantages?

  • Proprietary drug formulations and intellectual property.
  • Research collaborations with leading universities and research institutions.
  • Focus on niche markets with unmet medical needs.
  • Advanced stage clinical trials for lead drug candidate, Bucillamine.

What Does RVVTF Do?

Revive Therapeutics Ltd., incorporated in 2012 and headquartered in Toronto, Canada, is a life sciences company dedicated to the research and development of novel therapeutics for rare disorders and infectious diseases. The company's primary focus is on developing treatments utilizing cannabinoid and psilocybin-based pharmaceuticals. Revive's pipeline includes Bucillamine, a drug in Phase 3 clinical trials for infectious diseases, including influenza and COVID-19. Additionally, the company is developing Psilocybin, currently in Phase 1 clinical study, for treating methamphetamine use disorder. Further research is being conducted on Psilocin for mental health conditions such as depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. The company is also exploring cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics collaborates with PharmaTher Inc., North Carolina State University, University of California, San Francisco, and University of Health Sciences Antigua to advance its research and development efforts. These collaborations focus on areas such as psilocybin development for cancer treatment, biosynthetic psilocybin production, Bucillamine's potential for treating severe COVID-19, and clinical research of psychedelics.

What Products and Services Does RVVTF Offer?

  • Researches and develops therapeutics for rare disorders.
  • Focuses on treatments for infectious diseases.
  • Offers a cannabinoid pharmaceutical portfolio.
  • Develops Bucillamine for infectious diseases, including COVID-19.
  • Develops Psilocybin for treating methamphetamine use disorder.
  • Researches Psilocin for mental health conditions.
  • Explores cannabidiol for autoimmune hepatitis and organ transplantation injury.

How Does RVVTF Make Money?

  • Develops pharmaceutical products through in-house research and development.
  • Collaborates with universities and other research institutions to advance drug development.
  • Seeks regulatory approval for its drug candidates.
  • Plans to commercialize approved drugs through partnerships or direct sales.

What Industry Does RVVTF Operate In?

Revive Therapeutics operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory requirements. The industry is driven by the constant need for new and improved treatments for various diseases. Companies like Revive Therapeutics focus on niche markets, such as rare disorders and infectious diseases, to differentiate themselves. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. The development of novel therapies, particularly in areas like mental health and substance abuse, represents a significant growth opportunity within the industry.

Who Are RVVTF's Key Customers?

  • Patients suffering from rare disorders.
  • Patients with infectious diseases, including COVID-19.
  • Individuals with methamphetamine use disorder.
  • Patients with mental health conditions such as depression and anxiety.
  • Individuals with autoimmune hepatitis.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: Mar 15, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● No usable price
  • ● No filing on record
  • ● No analyst coverage

Company Profile

Revive Therapeutics Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, Canada.

How Revive Therapeutics Ltd. Is Valued

Revive Therapeutics Ltd. carries a market capitalization of $3.16M, placing it in the micro-cap category.

ROE 27%

Key Financial Metrics

Return on equity for Revive Therapeutics Ltd. stands at 26.8%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -1.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.04 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -11.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9

Financial Health

Revive Therapeutics Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

RVVTF Latest News

No recent news available for RVVTF.

RVVTF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for RVVTF.

Price Targets

Wall Street price target analysis for RVVTF.

RVVTF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for RVVTF; grades run from A+ (80-100) to F (below 30).

Leadership: Michael Frank

CEO

Michael Frank serves as the CEO of Revive Therapeutics Ltd. His background includes experience in managing and leading small teams within the life sciences sector. He is responsible for overseeing the company's research and development efforts, strategic partnerships, and overall corporate strategy. His leadership is focused on advancing the company's drug pipeline and securing regulatory approvals.

Track Record: Under Michael Frank's leadership, Revive Therapeutics has advanced Bucillamine to Phase 3 clinical trials for infectious diseases. He has also overseen the expansion of the company's research into psilocybin-based therapies and the establishment of strategic collaborations with universities and PharmaTher Inc. His focus has been on driving the company's drug development programs forward.

RVVTF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that Revive Therapeutics may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries a higher degree of risk due to the potential for less transparency and liquidity.

  • OTC Tier: OTC Other
Liquidity: As an OTC stock, RVVTF's liquidity may be limited compared to stocks listed on major exchanges. This can result in wider bid-ask spreads and greater price volatility. Investors may experience difficulty buying or selling large quantities of shares without significantly impacting the stock price. The trading volume should be carefully monitored to assess liquidity risks.
OTC Risk Factors:
  • Limited financial disclosure and transparency.
  • Lower liquidity and higher price volatility.
  • Potential for pump-and-dump schemes and other fraudulent activities.
  • Greater risk of delisting or trading suspensions.
  • Limited regulatory oversight compared to major exchanges.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if available).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Review the company's capitalization structure and potential dilution.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor before investing.
  • Understand the risks associated with OTC investments.
Legitimacy Signals:
  • Phase 3 clinical trials for Bucillamine.
  • Research collaborations with reputable universities.
  • Focus on developing therapeutics for unmet medical needs.
  • Company incorporated in 2012.

Common Questions About RVVTF (Healthcare)

What does Revive Therapeutics Ltd. do?

Revive Therapeutics Ltd. is a life sciences company focused on the research, development, and commercialization of novel therapeutics for rare disorders and infectious diseases.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on publicly available sources and may be subject to change.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives